Neurology Order Form







Fax completed	form to: 833-908-1122		specialty infusion service	ces	an amerita company an ar	nerita company
PATIENT INFORMATION						
Patient Name:	Date o	of Birth:			Referral Date:	
Address:				City/State/Zip	o:	
Home Phone:	Cell P	Phone:			Work Phone:	
Secondary Contact:	Heigh	ht:	Weight:		Male Female	
Patient Diagnosis & ICD-1	0:					
Allergies:						
PROVIDER INFORMATION						
Physician Name:	Lic.#:	:		DEA #:		
Practice Name:			+	NPI#:		
Address:	, n		City/State/Zip:			
Office Contact:	Phone	16:			Fax:	
Supervisory Physician (if applicable): PLEASE ATTACH						
	Patient demographics & front/back copy of all insurance cards (prescription & medical) Vaccine status (any vaccination) and documentation of any recent vaccinations UNIVIOLE and the status (any vaccination) and documentation of any recent vaccinations					
Recent office visit notes, history & physical, lab & pertinent procedure results HBV lab results within last 12 months (<i>Uplizna only</i>)						
Current medication list & list of prior medications tried and failed (with dates) Date of diagnosis, current FVC%, ALSFRS-R score, and JourneyMate form (Radicava only) Anti-acetylcholine receptor (AChR) antibody positive results (Vyvgart)						
	imunoglobulin lab results (<i>Uplizna only)</i>	Letter of medical necessity if drug dosing or indication is outside of FDA guidelines				
TB lab results within last 12 months (<i>Uplizna only</i>)						
NURSING & LAB ORDERS						
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.						
Flush Orders: Natice to provide assessment, teaching, hab draws, inedicated administration and vascular access device insertion and/or management per physician orders. Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mLOR 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line						
Lab Orders: Lab Date & Frequency:						
PRESCRIPTION ORDERS						
Anaphylaxis Kit: Epinephrine 0.3mg IM as needed Solu-cortef 250mg-500mg IV as needed Solu-Medrol 60mg - 125mg IV as needed						
(Check all that apply) Diphenhydraminemg IV as needed NS Hydration 500 ml IV over 30 minutes as needed Other						
Pre-Medications: Acetaminophenmg POminutes prior to infusion Solu-Medrolmg IVminutes prior to infusion						
(Check all that apply) Diphenhydraminemg POOR IVminutes prior to infusion Other						
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary						
PRODUCT		PRESCRI	PTION INFORMA	ATION		REFILLS
Is this a first dose? Yes No If No, when was last dose given? When is patient due for next dose?						
RADICAVA	Induction : 60mg IV infusion via gravity	OR pump o	over 1 hour daily for 14 days foll	owed by 14 da	ay drug-free period	NONE
	Maintenance: 60mg IV infusion via gravity OR pump over 1 hour daily for 10 days out of 14 day period followed by 14 day drug-free periods					
UPLIZNA	Induction: 300mg IV infusion via gravity	y 0R pump	over approximately 90 minute	s at 0 and 2 w	eeks and <i>CBC lab testing every months</i>	NONE
	Maintenance: (starting 6 months from first infusion) 300mg IV infusion via gravity OR pump over approximately 90 minutes every 6 months					
	100mg IV infusion via gravityOR pump over approximately 30 minutes every 12 weeks					
VYEPTI	300mg IV infusion via gravity oR pump over approximately 30 minutes every 12 weeks					
	10mg/kg V infusion via gravity OR pump over at least 1 hour once every week for 4 weeks					
VYVGART	*Up to max of 1200mg for patient weight of 120kg-			I 4 WCCK3		
	Administer additional treatment cycles every 50 days OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle					
		,			of initiating subsequent cycles sooner than 50 days	
	from the start of the previous treatment cycle has not been established.					
VYVGART HYTRULO	1,008mg/11,200 units subcutaneous injection over			weekly inject	tions for 4 weeks	
	Administer additional treatment cycles every 50 daysOR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle					
	According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days					
	from the start of the previous treatment cycle has not been established.					
IG	Refer to Immunoglobulin Form					
SOLIRIS/ULTOMIRIS	Refer to Soliris or Ultomiris Order Form					
OTHER						NONE
By signing this form and utilizing our services, you are authorizing Amerita to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.						

Prescriber's Signature **Dispense as Written**

Print Name

Date

Prescriber's Signature **Substitution Permitted** **Print Name**

Date



